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Abstract
Objectives Despite the availability of vaccines and the
existence of public vaccination recommendations, out-
breaks of vaccine-preventable childhood diseases still
cause public health debate. The objective of this systematic
review was to provide an overview of the current epi-
demiology and economic burden of measles, mumps,
pertussis, and varicella in Germany.
Methods We systematically reviewed studies published
since 2000. The literature search was conducted using
PubMed and EMBASE. Also, we used German notification
data to give an up-to-date overview of the epidemiology of
the four diseases under consideration.
Results Thirty-six studies were included in our review.
Results suggest that there is still considerable morbidity
due to childhood diseases in Germany. Studies providing
cost estimates are scarce. Comparative analyses of different
data sources (notification data vs. claims data) revealed a
potential underestimation of incidence estimates when
using notification data. Furthermore, several studies
showed regional differences in incidence of some of the
diseases under consideration.
Conclusions Our findings underline the need for improved
vaccination and communication strategies targeting all
susceptible age and risk groups on a national and local
level.
Keywords Childhood diseases  Epidemiology 
Economic burden  Germany
Introduction
Vaccination is regarded as one of the great public health
achievements (CDC 1999) and has led to substantial
decreases in morbidity and mortality of vaccine-pre-
ventable diseases (Roush and Murphy 2007). However,
despite the availability of vaccines and the existence of
public vaccination recommendations, vaccine-pre-
ventable childhood diseases are still a subject of public
health debate and research. This is mostly due to outbreaks
such as the large measles outbreak in Berlin in 2014/2015
(RKI 2015b).
In Germany, current vaccination recommendations of
the Standing Vaccination Committee (STIKO) cover,
among others, routine childhood vaccination against
measles, mumps, pertussis, and varicella (Table 1). Some
of these recommendations have existed for decades and
undergone several updates. A detailed description of the
history of vaccination recommendations in Germany was
published by Klein et al. (2012).
In many countries, the introduction of vaccination rec-
ommendations is accompanied by the implementation of
infectious disease surveillance systems. The primary aim of
such surveillance systems is to collect and analyse
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infectious disease data on an ongoing basis. These data can
be used to detect outbreaks and to evaluate the impact of
interventions. Surveillance data can be collected through
various methods including passive surveillance, active
surveillance, and sentinel surveillance (Declich and Carter
1994; MacDonald 2012; Oleckno 2008; Roush 2011):
• Passive surveillance mainly refers to national notifica-
tion systems based on mandatory case reporting. This
means that health care providers (e.g. physicians and
hospitals) and laboratories are required by law to
routinely report the occurrence of certain infectious
diseases to public health officials. Passive surveillance
is the most common method for collecting data on
vaccine-preventable diseases. It captures the entire
population and requires relatively few resources, but
completeness of reporting is highly dependent on the
compliance of health facilities. Moreover, diagnostic
accuracy can differ among health care providers,
particularly since case definition criteria of notification
systems often include not only laboratory-confirmed
cases but also clinically diagnosed cases.
• Active surveillance involves a proactive search for
cases by health authorities through contacting health
care providers on a regular basis. This data collection
procedure can provide a more complete picture of
disease frequency, but it is usually more costly than
passive surveillance. That is why active surveillance is
often limited to outbreaks or other short-term
investigations.
• Sentinel surveillance, which may comprise elements of
both active and passive surveillance approaches, relies
on a limited number of carefully selected reporting
sites. Selection criteria may include representativeness,
geographic area, and practical considerations related to
feasibility and reporting quality (e.g. willingness to
participate, well-qualified staff, and adequate technical
resources). Sentinel surveillance requires fewer
resources than population-based surveillance and can
provide high-quality data. The main shortcoming of
this approach is that the generalisability of the findings
may be limited.
Further data collection procedures include surveillance
surveys, epidemic field investigations and the use of sec-
ondary data sets (Declich and Carter 1994). In Germany,
measles has been a notifiable disease since 2001. Mumps,
pertussis, and varicella became notifiable on a national
level in March 2013 (Table 1). German sentinel systems
were, among others, developed for the surveillance of
measles (Siedler and Leitmeyer 2004) and varicella (Sie-
dler and Arndt 2010).
In 2010, the 53 member states of the World Health
Organization (WHO) European Region renewed theirT
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commitment to the elimination of measles by 2015 (WHO
2010). Nevertheless, the outbreak in Berlin in 2014/2015
(RKI 2015b) clearly demonstrates that Germany has not
met the elimination target so far. Therefore, the objective
of this study is to systematically review the existing liter-
ature on the current epidemiology and economic burden of
measles and other childhood diseases (namely mumps,
pertussis, and varicella) in Germany.
Epidemiological measures of interest include inci-
dence, frequency of complications and long-term
sequelae, mortality, outbreak descriptions, and disability-
adjusted life years (DALYs). The DALY is a summary
measure of population health that captures the burden of
morbidity and mortality in a single metric. DALYs for a
particular disease are calculated as the sum of the time
lost due to premature death and the time lived with poor
health or disability. The concept includes weighting of
disease duration with a weight factor that reflects the
severity of the health condition (Murray 1994). Since the
development of this measure in the early 1990s, the
methods used to calculate DALYs have undergone sev-
eral changes (Devleesschauwer et al. 2014; Murray et al.
2012; Voigt and King 2014). The DALY approach is
primarily used by the WHO to quantify the global bur-
den of disease.
Our definition of economic burden covers resource
consumption (particularly hospitalisation), illness-related
work days lost, and direct and indirect costs. Direct costs
primarily capture the cost of medical care (e.g. drug ther-
apy, physician consultations, inpatient treatment), whereas
indirect costs mainly refer to productivity losses due to
absence from work and premature death.
Methods
Literature search
We searched in the literature databases PubMed and
EMBASE for relevant papers published between 1 Jan-
uary 2000 and 8 February 2015. Search terms included
controlled vocabulary and free-text terms. Details of the
search strategy are provided in the supplementary
material (Online Resource 1). Two investigators (OD
and JW) independently screened search results and
assessed the eligibility of potentially relevant studies
according to predefined inclusion and exclusion criteria.
Discrepancies were solved through discussion involving
a third investigator (SW). Reference lists of identified
studies were searched manually for further relevant
publications. We followed the PRISMA guidelines for
conducting and reporting systematic reviews (Moher
et al. 2009).
Inclusion and exclusion criteria
We included English and German language articles
reporting data on the epidemiology and economic burden
of measles, mumps, pertussis, and varicella in Germany.
We did not apply restrictions concerning the type of study
and the method of data collection. We wanted to focus as
far as possible on the general population and, therefore,
excluded studies restricted to health care workers, military
personnel and their families. We also excluded pure review
articles, comments, letters, editorials, single case-reports,
small case series and outbreak reports with fewer than 10
subjects, articles without full-text (e.g. conference
abstracts), and surveillance and outbreak reports lacking a
separate methods section.
Data extraction
Data extraction was performed by one investigator (OD)
and verified by a second (JW). The following data were
abstracted from the included studies: type of study, data
sources and methods, population and setting, time frame,
outcome measures, and results.
Surveillance data
In addition to our literature search, we used notification
data of the German Protection against Infection Act (In-
fektionsschutzgesetz) to give an up-to-date overview on the
epidemiology of measles, mumps, pertussis, and varicella
in Germany. The numbers of notified cases were extracted
using a web-based data query tool (SurvStat@RKI 2.0).
Results
Literature review
After duplicates were removed, the bibliographic search
using PubMed and EMBASE databases yielded 1700
records. After screening of titles and abstracts, 1568 records
were excluded and 132 full-text articles were subsequently
assessed for eligibility. Ninety-six articles were excluded
after full-text assessment. Main reasons for exclusion were
study objective (e.g. vaccination coverage or vaccine
effectiveness), publication type (e.g. review article, case
report, or comment), or lack of a sufficient methods sec-
tion. Thirty-six studies fulfilled the inclusion criteria and
were, therefore, included in this review. Figure 1 shows the
process of study identification and selection.
Of the 36 included studies, 18 reported results for
measles, two for mumps, six for pertussis, and ten for
varicella. Most of the studies were mainly based on data
Epidemiology and economic burden of measles, mumps, pertussis, and varicella in Germany… 849
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from (mandatory) notification and/or sentinel surveillance
systems. Four of these studies used data from a paediatric
hospital-based surveillance system, called ESPED (Erhe-
bungseinheit für seltene pädiatrische Erkrankungen in
Deutschland; German paediatric surveillance unit). Three
studies used claims data of the Associations of Statutory
Health Insurance Physicians (ASHIP). Two studies
explicitly applied (decision-analytic) modelling approa-
ches. Other methods and data sources used include survey
and interview methods, contact tracing activities, and
review of medical files or national statistics. The majority
of the included studies (n = 34) provided data on epi-
demiological outcomes and/or hospitalisation. Only few
studies reported on economic aspects in terms of costs and/
or work days lost (n = 5). Table 2 summarises the char-
acteristics and results of the included studies. The main
results are also described in the following paragraphs.
Measles
Incidence estimates based on analyses of surveillance data
ranged widely across studies and years (from\0.1 to 38.9
per 100,000 inhabitants per year). Outbreak-related inci-
dence estimates ranged between 12 and 32 per 100,000
inhabitants. One study examining the epidemiology of
measles from 2007 to 2011 (Takla et al. 2014) showed large
geographical differences in incidence of measles with the
highest incidence in southern Germany. Another study pre-
senting results for 1999 to 2001 (Tischer et al. 2002) found
thatmost cases ofmeasles occurred in southernGermany and
in North Rhine-Westphalia. Two studies (Mette et al. 2011;
Takla et al. 2014) compared results of the analyses of
surveillance data and ASHIP claims data and found that
incidence estimates based on ASHIP data were higher than
estimates based on notification data. Some studies only
reported absolute numbers of cases instead of presenting data
as incidence rates (see Table 2 for details). The proportion of
patients developing any complications varied from 15 to
24 %. The most frequent complications of measles were
otitis media and pneumonia. In hospitalised children, pneu-
monia was diagnosed in more than 50 % of the patients
(Arenz et al. 2009). The proportion of measles-associated
hospitalisations ranged from 2.2 to 40 % in studies exam-
ining all ages. One study found a proportion of
Records identified through database searching 
(PubMed: n = 586; EMBASE: n = 1578)
Additional records identified through other 
sources (n = 0)
Records after duplicates removed (n = 1700)
Records screened (n = 1700) Records excluded (n = 1568)
Full-text articles assessed for eligibility (n = 132) Full-text articles excluded (n = 96):
- publication type (n = 50)
- study objective (n = 30)
- no (sufficient) methods section (n = 10)
- study population (n = 3)
- no German data (n = 3)
Studies included in synthesis (n = 36)
Fig. 1 Flowchart of the study identification and selection process
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Table 2 Study characteristics and results
Publication Methods (study type, data source,
population, and time frame)
Outcome measures Results
Measles
Arenz et al.
(2009)
Analysis of surveillance data; paediatric
hospital-based surveillance data (ESPED);
hospitalised children and
adolescents\16 years (detailed
questionnaire-based information was
obtained for 96 children); 2006
Children hospitalised for measles 115 children (42 % were\2 years)
Median length of hospital stay 6 days
Complications Pneumonia: 54 %; otitis media: 11 %; seizures:
7 %
Measles-related deaths 2 children died of measles (with encephalitis)
Carabin
et al. (2003)
Multi-country cost study; country-specific
incidence and cost data; direct costs include
physicians’ visits, prescription medication,
hospitalisation, and long-term care for
sequelae; general population in Germany;
2001
Average annual costs (2001 values) of
caring for measles per capita in
Germany from a health care
provider perspective
Approximately EUR 0.02 per capita
Gillesberg
Lassen
et al. (2014)
Outbreak report; notification data and clinical
data collected through interviews with case-
patients; community members, students of an
anthroposophic school, and family members
and friends of the students in Berlin; April–
July 2011
Cases of measles 73 cases (27 % of all case-patients and 38 % of
community case-patients were C20 years)
Hospitalisation 15 %
Hegasy et al.
(2012)
Outbreak report; notification data and contact
tracing activities; non-Roma inhabitants and
Roma community members living in
Hamburg; December 2008–June 2009
Cases of measles 216 cases (69 % were confirmed by laboratory
analyses); a local Roma community
comprised more than 50 % of the notified
cases
Mankertz
et al. (2011)
Study on spread of the D4-Hamburg strain;
results of laboratory samples; general
population in Germany; 2008–2010
Cases of measles 216 cases in Hamburg; 72 cases in Lower
Saxony; 48 cases in Munich; several cases
occurred in Roma community members and
asylum seekers
Hospitalisation 40 % of patients (due to pneumonia or otitis
media)
Mette et al.
(2011)
Claims data analysis and comparison with
surveillance data; ASHIP billing data and
notification data; 15.4 million people
covered by statutory health insurance living
in North Rhine-Westphalia; 2006–2007
Confirmed measles diagnoses (ASHIP
data)
2534 diagnoses (87 % of billed measles
diagnoses occurred in children\10 years)
Reported cases of measles
(notification data)
2014 cases (40 % of measles cases were
reported for children\10 years)
Ratio of confirmed measles diagnoses
and reported cases of measles
1.26: 1 (underreporting)
Muscat et al.
(2009)
Multi-country analysis of surveillance data;
data of national mandatory notification
systems; general population in Germany;
2006–2007
Cases of measles 2307 cases in 2006; 571 cases in 2007
Incidence per 100,000 inhabitants 2.8 per 100,000 in 2006; 0.7 per 100,000 in
2007
Measles-related deaths 2 fatal cases in children (caused by
encephalitis)
Muscat et al.
(2014)
Multi-country analysis of surveillance data;
data submitted by national surveillance
institutions to the WHO Regional Office for
Europe; general population in Germany;
2012–2013
Cases of measles 167 cases in 2012; 1773 cases in 2013
Incidence per million inhabitants per
year
2 per million in 2012; 21.4 per million in 2013
Plass et al.
(2014)
Burden of disease study; DALY estimates are
based on a model of the natural history of
disease using notification data; general
population in Germany; 2005–2007
Average loss of DALYs per year 740 DALYs (93 % was due to acute
symptomatic infections and 7 % was due to
long-term sequelae)
Average loss of DALYs per case 0.26 DALYs
Roggendorf
et al. (2012)
Outbreak report; surveillance data of a
community health centre; 1st outbreak:
children attending a free progressive school
in Essen and their contacts; 2nd outbreak:
children and adults in a low socio-economic
setting and with migration background in
Essen; March–July 2010
Cases of measles 1st outbreak: 75 cases; 2nd outbreak: 11 cases
Hospitalisation 15 %
Siedler et al.
(2006)
Outbreak report; surveillance data of the
mandatory reporting system and data
collected through interviews of the local
health authorities with physicians and family
members; general population in Hesse and
Bavaria; January–May 2005 (Hesse) and
March–July 2005 (Bavaria)
Cases of measles (without sporadic
cases)
Hesse: 223 cases; Bavaria: 279 cases; 74 % in
school aged children
Incidence per 100,000 inhabitants Hesse: 14 per 100,000; Bavaria: 12 per 100,000
Hospitalisation in patients C20 years Outbreak in Hesse: 34 %
Measles-related deaths Outbreak in Hesse: 1 case
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Table 2 continued
Publication Methods (study type, data source,
population, and time frame)
Outcome measures Results
Siedler et al.
(2013a)
Analysis of surveillance data; sentinel data
collected by 1488 paediatric and primary
care practices; patients of practices
participating in the sentinel system;
2001–2010
Cases of measles 3100 cases (2495 cases in children\10 years)
Complications 15 % (mostly otitis media and pneumonia)
Takla et al.
(2014)
Claims data analysis and comparison with
surveillance data; ASHIP billing data and
mandatory notification data; 68 % (2007)
and 79 % (2008–2011) of the total
population living in Germany (ASHIP data);
2007–2011
Cases of measles (notification data) 4440 cases
Annual incidence per million
population (notification data)
Total: 10.8 per million (range 6.9–19.6 per
year); northern Germany: 8.7; western
Germany: 7.2; eastern Germany: 5.5;
southern Germany: 20.3
Annual incidence per million residents
with statutory health insurance
(ASHIP data)
27.5 per million; incidence based on ASHIP
data was up to 4.8-fold higher than incidence
based on notified cases
Tischer et al.
(2001)
Analysis of surveillance data; sentinel data and
notification data; general population in
Germany; October 1999–March 2001
Cases of measles (sentinel data) 1291 cases
Complications (sentinel data) 24 %
Hospitalisation (sentinel data) 2.2 %
Incidence per 100,000 inhabitants 38.9 per 100,000 (sentinel data);\0.5–5.7 per
100,000 (notification data of the first quarter
of 2001)
Tischer et al.
(2002)
Analysis of surveillance data; sentinel data
collected by 1271 paediatric and primary
care practices; general population in
Germany; October 1999–September 2001
Cases of measles 1720 cases
Incidence per 100,000 inhabitants 20 per 100,000 (range\1–56 per 100,000,
depending on the federal state)
Complications 16 % (mostly otitis media and pneumonia)
Hospitalisation 2.4 %
Wadl et al.
(2011)
Outbreak report; surveillance data and data
collected through questionnaires; general
population in four Bavarian counties
(including attendees of an anthroposophic
school in Austria); March–July 2008
Cases of measles 217 cases
Incidence per 100,000 population 32 per 100,000
Hospitalisation 11 %
Complications 18 %
Wichmann
et al. (2007)
Retrospective cohort study on the initial phase
of an outbreak; data collected through
questionnaires; 1098 students aged
10–21 years of a public day school in
Duisburg; January–May 2006
Cases of measles 53 cases
Hospitalisation 4 %
Complications Otitis media: 4 cases; pneumonia: 1 case;
encephalitis: 1 case
Wichmann
et al. (2009)
Study on outbreak-related morbidity and costs;
surveillance data and data collected through
questionnaires/interviews (face-to-face or by
telephone); health care provider costs
(including physician consultations,
laboratory tests, antibiotic treatment, and
hospitalisation) are calculated using DRGs,
the outpatient fee schedule and medication
prices; general population in Duisburg; 2006
Cases of measles 614 cases in Duisburg
Hospitalisation 15 %
Antibiotic treatment 32 %
Complications Otitis media: 19 %; pneumonia: 7 %;
encephalitis: 0.6 %
Measles-related deaths 2 fatal cases in children (caused by
encephalitis)
School days missed 2854 days
Work days lost 301 days
Average costs (2006 values) EUR 373 per measles patient; EUR 1877 per
hospitalised patient
Mumps
Otto et al.
(2010)
Outbreak report; laboratory samples and
clinical data; adolescents and young adults in
Bavaria; July–October 2010
Laboratory-confirmed infections 115 laboratory-confirmed mumps infections
(median age: 24.5 years, predominantly male
patients)
Complications 1 case of meningitis and 21 cases of orchitis
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Table 2 continued
Publication Methods (study type, data source,
population, and time frame)
Outcome measures Results
Takla et al.
(2013)
Claims data analysis and comparison with
surveillance data; ASHIP billing data and
notification data; statutory health-insured
population and general population in the
eastern and western federal states of
Germany; 2007–2011
Countrywide mean annual incidence
per 100,000 people covered by
statutory health insurance
10.3 per 100,000 (range 9.3–11.8); incidence
was significantly higher in western than in
eastern federal states; comparison of
notification data with ASHIP data indicated
severe underreporting of incidence estimates
based on notification data
Complications Orchitis: 6.2 % of male cases; meningitis:
0.4 %; pancreatitis: 0.3 %; encephalitis:
0.2 %; proportion of complications in
cases C15 years was significantly higher
than in cases\15 years
Pertussis
Hellenbrand
et al. (2009)
Analysis of surveillance data; surveillance data
(notification and sentinel data) and hospital
discharge statistics; general population in
Germany; 2000–2007
Incidence per 100,000 inhabitants in
eastern federal states (notification
data)
20.5 per 100,000 in 2000; 39.3 per 100,000 in
2007
Incidence in adults per 100,000
inhabitants
160–169 per 100,000 in 2002–2004
Hospitalisation in eastern federal
states (surveillance data)
1.9–4.9 % in 2002–2007 (depending on the
federal state)
Hospitalisation (cases per 100,000
population, hospital discharge
statistics)
1.7 per 100,000 in eastern federal states in
2007; 1.5 per 100,000 in western federal
states in 2005; most cases occurred in
children\1 year
Juretzko
et al. (2001)
Analysis of surveillance data; paediatric
hospital-based surveillance data (ESPED)
and clinical data collected through
questionnaires; children\16 years;
1997–1998
Standardised incidence of pertussis
requiring hospitalisation per
100,000 person-years
2.70 per 100,000; 2.36 per 100,000 in western
federal states; 4.50 per 100,000 in eastern
federal states
Mean length of hospital stay 14.9 days
Complications in hospitalised children All: 44 % (60 % occurred in
children\6 months); pneumonia: 28.1 %;
apnea: 20.6 %; seizures: 2.5 %;
encephalopathy: 2.1 %
Pertussis-related deaths in hospitalised
children
0.3 %
Liese et al.
(2003)
Prospective long-term surveillance study;
follow-up data of a population-based case–
control efficacy study; 11,087 children
(3–8 years) of the original study population
and all other children of the same age group
presenting in the participating paediatric
practices; 8.3 % were not vaccinated against
pertussis; May 1997–March 1999
Cases of pertussis 180 cases; 64 % were caused by B pertussis
infections and 36 % were caused by B
parapertussis infections
Incidence per 1000 person-years B pertussis infections: 4.8 per 1000; B
parapertussis infections: 2.8 per 1000
Riffelmann
et al. (2006)
Prospective incidence and cost study;
laboratory samples, clinical and resource
consumption data collected through
questionnaires; direct costs include physician
consultations, laboratory tests, and
medication; indirect costs are based on the
number of work days lost and a cost of EUR
114.30 per day; 971 primary care patients
having cough for C7 days in two German
cities (Krefeld and Rostock); economic
analysis is based on 45 cases of pertussis;
2001–2004
Proportion of patients with pertussis 10 %
Incidence per 100,000 inhabitants 165 per 100,000
Pertussis patients with antibiotic
prescription
53 %
Average direct costs (2004 values) per
case
EUR 120
Average indirect costs (2004 values)
per case in employed patients
EUR 2443
Sin et al.
(2009)
Outbreak report; active case finding by the local
health authorities and a retrospective cohort
study performed in 4 affected schools
(questionnaires); mostly children and
adolescents attending schools in Ludwigslust
district, Mecklenburg-Western Pomerania;
2005–2006
Cases of pertussis 104 cases
Attack rate 1.9–32.0 % (depending on the time since last
vaccine dose); results suggest that vaccine-
induced immunity begins to wane
approximately 5 years after completion of
the primary series
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Table 2 continued
Publication Methods (study type, data source,
population, and time frame)
Outcome measures Results
Stojanov
et al. (2000)
Prospective surveillance study; data of a case–
control efficacy study; 11,016
children\2 years presenting with
cough B7 days at 63 paediatric practices in
Germany; March 1993–May 1995
Proportion of patients with pertussis 6.6 %
Hospitalisation 4.5 %
Complications in hospitalised
pertussis patients
All: 48 %; bradycardia: 21 %; apnea: 12 %;
conjunctivitis: 12 %; pneumonia: 6 %; otitis
media: 6 %
Mean length of hospital stay 8 days
Varicella
Banz et al.
(2004)
Cost study; cost estimates are based on a
decision-analytic model using survey data
(Wagenpfeil et al. 2004); direct costs include
physician consultations, medication, and
hospitalisation; transfer payments are based
on parental work days lost; indirect costs are
based on the number of work days lost and a
cost of EUR 150 per day; general population
in Germany; 1999 prices (pre-vaccination
era)
Annual third-party payer costs (1999
values of direct costs and transfer
payments to parents caring for their
sick children)
EUR 78 million (direct medical costs: 43 %)
Annual societal costs (1999 values of
direct and indirect costs)
EUR 187.5 million (direct medical costs: 18 %)
Grote et al.
(2007)
Analysis of surveillance data; paediatric
hospital-based surveillance data (ESPED);
paediatric population up to the age of
17 years; 2003–2004 (pre-vaccination era)
Cases of varicella-associated deaths 10 cases (none was vaccinated against
varicella)
Annual mortality rate (cases per
million children)
0.4 per million
Liese et al.
(2008)
Analysis of surveillance data; nationwide
paediatric hospital-based surveillance data
(ESPED), practice sentinel network and
hospital diagnosis data in one federal state
(North Rhine-Westphalia);
children B16 years; 2003–2004 (pre-
vaccination era)
Hospitalised varicella cases (ESPED
data)
918 cases (with a median age of 3.3 years)
Annual incidence of varicella-related
hospitalisations (cases per 100,000
children)
3.25 per 100,000 (ESPED data); 14.1 per
100,000 (capture–recapture methodology for
two sources); 19.7 per 100,000 (hospital
diagnosis data)
Median length of hospital stay 5 days
Complications in hospitalised cases All: 79.6 %; neurological: 25.4 %; skin:
23.2 %; gastrointestinal tract: 15 %; lower
respiratory tract: 11.8 %; severe systemic
bacterial infections: 4.4 %
Cases of varicella-associated deaths 10 cases
Siedler and
Arndt
(2010)
Analysis of surveillance data; sentinel data
collected by paediatricians and general
practitioners; general population in
Germany; April 2005–March 2009
(vaccination era)
Cases of varicella and trend analysis 83,181 cases; sentinel data showed a reduction
of 55 % of varicella cases in all ages over
time
Siedler et al.
(2013b)
Analysis of surveillance data; sentinel data,
notification data, and hospital diagnosis
statistics; general population in Germany;
2005–2012 (vaccination era)
Trend analysis of varicella-related
morbidity
Significant decline of varicella incidence,
complications, and hospitalisations over time
Siedler and
Dettmann
(2014)
Analysis of hospitalisation data; national
hospital discharge statistics; general
population in Germany; 1995–2012 (pre-
vaccination era and vaccination era)
Trend analysis of varicella
hospitalisation incidence
No particular trend until 2003, hospitalisation
incidence peaked in 2004 (time of vaccine
recommendation), and decreased thereafter;
hospitalisation incidence per 100,000 was
significantly lower in the vaccination period
(1.86) than in the pre-vaccination period
(3.30)
Spackova
et al. (2010)
Analysis of surveillance data; sentinel data
collected by paediatricians and general
practitioners; general population in
Germany; April 2005–March 2009
(vaccination era)
Cases of varicella and trend analysis 83,075 cases; the total number of varicella
cases decreased over time with increasing
vaccine uptake
Complications All: 0,34 %; bacterial superinfection: 0.13 %;
otitis media: 0.06 %; neurological: 0.03 %
Hospitalisation in varicella patients
with complications
25 %
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hospitalisation of 34 % in patients B20 years (Siedler et al.
2006). Median length of hospital stay in children was 6 days
(Arenz et al. 2009). Four studies provided information on
measles-related deaths, which occurred rarely and only in
children (see Table 2 for details). In a German substudy of
the Burden of Communicable Diseases in Europe (BCoDE)
project, the average loss of DALYs per case of measles was
estimated to be 0.26 resulting in an average DALY loss per
year of 740 (Plass et al. 2014). The average costs per measles
patient and per hospitalisation were EUR 373 and 1877,
respectively (Wichmann et al. 2009).
Mumps
Mean annual incidence of mumps based on claims data was
estimated to be 10.3 per 100,000 people covered by
statutory health insurance. Incidence was significantly
higher in western federal states than in eastern federal
states. A comparison between claims data and notification
data indicated severe underreporting of mumps incidence
in the notification surveillance system (see Table 2 for
details). The main complication was orchitis affecting
6.2 % of male cases. The proportion of complications in
individuals C15 years was higher than in younger patients
(Takla et al. 2013). Information on the economic burden of
mumps was not available.
Pertussis
In children, incidence of infections with Bordetella per-
tussis and Bordetella parapertussis was 4.8 and 2.8 per
1000 person-years, respectively. More than 60 % of all
pertussis cases in children from 3 to 8 years were caused
by Bordetella pertussis (Liese et al. 2003). Incidence of
pertussis requiring hospitalisation was 2.7 per 100,000
person-years in children (Juretzko et al. 2001). In adults,
incidence of pertussis ranged from 160 to 169 per 100,000
inhabitants (Hellenbrand et al. 2009). The diagnosis of
pertussis could be verified in 10 % of the primary care
patients having cough for C7 days (Riffelmann et al.
2006). In children\2 years presenting with cough
for C7 days, pertussis was diagnosed in 6.6 % of the cases
(Stojanov et al. 2000). Pertussis-associated hospitalisation
rate was 1.5 and 1.7 per 100,000 population in the western
and eastern federal states, respectively (Hellenbrand et al.
2009). Most of the hospitalisations occurred in
Table 2 continued
Publication Methods (study type, data source,
population, and time frame)
Outcome measures Results
Streng et al.
(2013)
Analysis of surveillance and survey data; data
of the Bavarian Varicella Surveillance
Project (BaVariPro) based on parent surveys
(vaccination coverage), paediatric practice
surveillance, and paediatric hospital database
queries; children\17 years in Munich;
October 2006–September 2011 (vaccination
era)
Cases of varicella and trend analysis 16,054 cases; the mean number of cases
decreased by 67 % during the five seasons
Incidence per 1000 children (based on
the number of reported cases)
26 per 1000 in the first season and 6 per 1000 in
the fifth season
Complications in practice patients 0.8 % (mostly skin complications and otitis
media)
Complications in hospitalised patients Central nervous system: 22.5 %; skin: 15.7 %;
lower respiratory tract: 9 %
Median length of hospital stay 3 days
Hospitalisation incidence (cases per
100,000 children) and trend
analysis
8.2 per 100,000; hospitalisation incidence
decreased by 43 % between 2005 and 2009
Wagenpfeil
et al. (2004)
Retrospective epidemiological and resource
consumption study; clinical data were
obtained from medical files through
telephone interviews with physicians; 1334
unvaccinated varicella patients of a
representative and German-wide sample of
paediatric and primary care practices; 1999
(pre-vaccination era)
Complications All: 5.7 %; bacterial superinfection: 2.5 %
(B12 years), 1.9 % ([12 years);
neurological: 0.2 % (B12 years); pneumonia
or bronchitis: 1.9 % (B12 years), 1.9 %
([12 years); otitis media: 1.1 % (B12 years)
Hospitalisation period per diagnosed
varicella case
0.1 inpatient days
Work days lost per diagnosed varicella
case
1.3 days
Ziebold
et al. (2001)
Analysis of surveillance data; paediatric
hospital-based surveillance data (ESPED)
and clinical data collected through
questionnaires; hospitalised
children B16 years; 1997 (pre-vaccination
era)
Hospitalised varicella cases 119
Complications in hospitalised
varicella cases
Neurological: 62.3 %; infectious: 35.2 %
ASHIP Associations of Statutory Health Insurance Physicians, BaVariPro Bavarian Varicella Surveillance Project, DALY disability-adjusted life
year, DRG diagnosis-related group, ESPED Erhebungseinheit für seltene pädiatrische Erkrankungen in Deutschland (German paediatric
surveillance unit), WHO World Health Organization
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children\1 year (Juretzko et al. 2001). More than 40 % of
hospitalised children suffered from complications, and the
mean length of hospitalisation in children varied between 8
and 14.9 days (Juretzko et al. 2001; Stojanov et al. 2000).
Direct costs per case of pertussis were EUR 120 in primary
care patients, and indirect costs per case were EUR 2443 in
employed patients (Riffelmann et al. 2006). None of the
reviewed studies focused on older adults ([60 years).
Varicella
Studies analysing surveillance data from the vaccination
era showed a decline of varicella incidence and hospi-
talisations over time and with increasing vaccine uptake
(Siedler and Arndt 2010; Siedler et al. 2013b; Siedler
and Dettmann 2014; Spackova et al. 2010; Streng et al.
2013). The proportion of patients with complications
was higher in the pre-vaccination era (5.7 %) (Wa-
genpfeil et al. 2004) than in the vaccination era
(0.34–0.8 %) (Spackova et al. 2010; Streng et al. 2013).
Annual incidence of varicella-related hospitalisations
varied from 3.25 to 19.7 per 100,000 children depending
on the data source used before routine childhood vac-
cination against varicella was implemented (Liese et al.
2008). About 80 % of these (hospitalised) children suf-
fered from varicella-related complications, and most
frequent complications were neurological and infectious
complications (Liese et al. 2008; Ziebold et al. 2001). In
the pre-vaccination era, annual varicella-associated
mortality in children was 0.4 per million (Grote et al.
2007), and societal costs of varicella were estimated at
EUR 187.5 million per year (Banz et al. 2004). How-
ever, direct medical costs accounted for only 18 % of
these costs. Work days lost per diagnosed varicella case
were 1.3 days (Wagenpfeil et al. 2004).
Analysis of surveillance data
The numbers of reported cases of measles, mumps, per-
tussis, and varicella over time are shown in Fig. 2.
Nationwide mandatory notification of measles was intro-
duced in 2001. Since then, the number of reported cases of
measles varied from year to year. Mumps, pertussis, and
varicella became officially notifiable diseases in Germany
in 2013. Hence, the numbers of notified cases of these
diseases strongly increased from that point of time. In
2014, about 70 % of all reported mumps and pertussis
cases occurred in adults, while most of the notified vari-
cella cases occurred in children. For the period before
2013, notification data on mumps, pertussis, and varicella
were available only for federal states in the eastern part of
Germany (see dotted lines in Fig. 2).
Discussion
Our review examined available information on the epi-
demiology and economic burden of measles, mumps,
pertussis, and varicella in Germany. In general, results
differed widely by reporting year, population, and data
source used. More specific key findings are discussed
below.
Results of the studies investigating the measles epi-
demiology in Germany and latest reports on the ongoing
outbreak in Berlin (RKI 2015b) clearly showed that Ger-
many has failed in achieving the aim of eliminating measles
until 2015. Some of the reviewed studies found huge
regional difference in measles incidence. Most cases
occurred in the context of regionally limited outbreaks, and
several outbreaks were linked to transmission from Roma
community members, asylum seekers, or anthroposophic
communities/schools. These findings are in line with a
recently published analysis of the measles epidemiology in
2014/2015 by the RKI (2015b) and indicate the importance
of conducting more in-depth analyses at a regional level,
increasing public awareness on the benefits of immunisation,
and strengthening efforts to identify and close the existing
vaccination gaps. The relevance of targeting vulnerable
groups such as Rome communities, anthroposophic groups,
and immigrants has already been emphasised by an over-
view of affected groups in Europe (Muscat 2011).
Comparative analyses of different data sources (notification
data vs. claims data) revealed a potential underestimation of
measles incidence estimates when using notification data.
Hence, claims data analyses should be used more regularly
to complement analyses based on surveillance systems and
to provide a more comprehensive picture of the epidemiol-
ogy of notifiable diseases in Germany.
Compared to measles, only very few studies have dealt
with the epidemiology of mumps in Germany. However,
some of the findings concerning measles also hold true for
mumps such as the underreporting of incidence estimates
based on surveillance data. Another similarity was found
between mumps and pertussis: in 2014, about 70 % of all
notified cases occurred in adults. Studies from other
countries have also reported an increasing incidence of
pertussis in adolescents and adults (Rothstein and Edwards
2005; McGuiness et al. 2013). Moreover, there is evidence
that adults are one of the major sources of pertussis in
infants (Orenstein 1999; Bisgard et al. 2004) and play a
crucial role in transmitting pertussis to household members
(Baptista et al. 2009). The reason for the age shift of per-
tussis is supposed to be the combination of less boosting by
natural infections and waning of vaccine-induced immu-
nity (Nitsch-Osuch et al. 2013). One of the reviewed
studies showed that pertussis was a common cause of
persistent cough in adults, which is in line with published
856 O. Damm et al.
123
data from other countries (Rothstein and Edwards 2005). In
general, it is assumed that standard surveillance systems
greatly underestimate the level of pertussis (Crowcroft and
Pebody 2006).
Several of the included studies on varicella reported on
the situation in the pre-vaccination era. Studies that are more
current showed that varicella incidence and hospitalisation
have decreased after the implementation of routine child-
hood vaccination. Similar effects have been observed after
the introduction of the varicella vaccination programme in
the United States (Marin et al. 2008; Baxter et al. 2014).
Furthermore, the overall decline in varicella incidence and
hospitalisation in the United States was not associated with a
shift to older age groups (Baxter et al. 2014).
Our review revealed that information on direct and
indirect costs of childhood diseases in Germany is scarce.
Furthermore, not all studies that collected cost data inclu-
ded all relevant cost components. For example, in the study
by Riffelmann et al. (2006), direct costs were calculated
without considering hospitalisation cost. In contrast, the
study by Banz et al. (2004) considered an additional cost
category when adopting a third-party payer perspective,
namely transfer payments to parents that stay at home to
care for their sick children. Inclusion of this cost category
can substantially increase costs from the health care payer
perspective, particularly when assuming that all sick
children cause parental absence from work. For instance, in
the study by Banz et al. (2004), the mean number of par-
ental work days lost per sick child ranged from 0.6 to 4
depending on the course of disease, and as a consequence,
the reimbursed costs of parental work days lost accounted
for 57 % of the total third-party payer costs.
The use of different outcome measures also hampers the
comparison of economic results across studies. The study
by Carabin et al. (2003), which estimated the costs of
measles for 11 countries, used per capita costs (approxi-
mately EUR 0.02) as economic outcome measure, whereas
the study by Wichmann et al. (2009) presented results in
terms of costs per measles patient (EUR 373) and costs per
hospitalised patient (EUR 1877).
In summary, since only few studies have provided cost
estimates so far, future research should concentrate on
quantifying the economic burden of disease. A more
intensified use of claims data analyses might contribute to
this aim. Also, administrative data from health insurance
funds might provide a good foundation to supplement
surveillance data (Jones et al. 2013) and to extend existing
methods of measuring underreporting of notified cases of
infectious diseases (Gibbons et al. 2014). However, as
current case definitions include not only laboratory-con-
firmed cases but also clinically diagnosed cases (RKI
2015a), notification data might also be subject to
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Fig. 2 Numbers of notified cases of measles, mumps, pertussis, and
varicella in Germany (2001–2015) based on SurvStat@RKI 2.0.
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overestimation. Certainly, the same is true for health
insurance claims data, since the validity of the recorded
diagnoses is largely unknown.
Limitations
There are several limitations of our systematic review.
First, since the scope of our review was limited to studies
presenting results for Germany, transferability of results to
other countries is limited, too. Second, due to the high
heterogeneity of the included studies, an assessment of
methodological quality was not performed. Third, many of
the included studies were based on surveillance data that
might be subject to underreporting. Fourth, case definitions
varied among studies, which might partially explain dif-
ferences in results.
Conclusions
This review aimed to provide an overview of the epi-
demiology and economic burden of measles, mumps,
pertussis, and varicella in Germany. Most of the reviewed
studies presented epidemiological outcomes. Studies pro-
viding information on economic aspects except
hospitalisation were scarce.
Despite the existing immunisation recommendations,
results suggest that there is still considerable morbidity due
to childhood diseases in Germany. However, not only
children are affected. For instance, a high proportion of all
pertussis cases occurs in adults. Furthermore, several
studies revealed regional differences in incidence of some
of the target diseases. These findings underline the need for
improved vaccination and communication strategies tar-
geting all susceptible age and risk groups on a national and
local level.
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Mulders MN, Santibanez S (2011) Spread of measles virus D4-
Hamburg, Europe, 2008-2011. Emerg Infect Dis 17:1396–1401
Marin M, Meissner HC, Seward JF (2008) Varicella prevention in the
United States: a review of successes and challenges. Pediatrics
122:e744–e751
McGuiness CB, Hill J, Fonseca E, Hess G, Hitchcock W, Krishnara-
jah G (2013) The disease burden of pertussis in adults 50 years
old and older in the United States: a retrospective study. BMC
Infect Dis 13:32
Mette A, Reuss AM, Feig M, Kappelmayer L, Siedler A, Eckmanns
T, Poggensee G (2011) Under-reporting of measles—an evalu-
ation based on data from North Rhine-Westphalia. Dtsch Arztebl
Int 108:191–196
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred
reporting items for systematic reviews and meta-analyses: the
PRISMA statement. David Moher and colleagues introduce
PRISMA, an update of the QUOROM guidelines for reporting
systematic reviews and meta-analyses. BMJ 339:332–336
Murray CJL (1994) Quantifying the burden of disease: the technical
basis for disability-adjusted life years. Bull World Health Organ
72:429–445
Murray CJL, Ezzati M, Flaxman AD, Lim S, Lozano R, Michaud C,
Naghavi M, Salomon JA, Shibuya K, Vos T, Wikler D, Lopez
AD (2012) GBD 2010: design, definitions, and metrics. Lancet
380:2063–2066
Muscat M (2011) Who gets measles in Europe? J Infect Dis
204:353–365
Muscat M, Bang H, Wohlfahrt J, Gilsmann S, Mølbak K, Measles in
Europe: An epidemiological assessment (2009) Measles in
Europe: an epidemiological assessment. Lancet 373:383–389
Muscat M, Shefer A, Ben Mamou M, Spataru R, Jankovic D,
Deshevoy S, Butler R, Pfeifer D (2014) The state of measles and
rubella in the WHO European Region, 2013. Clin Microbiol
Infect 20:12–18
Nitsch-Osuch A, Korzeniewski K, Kuchar E, Zielonka T, _Zycińska K,
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